⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2024Open Access

Supplementary Figure S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers

Patricia J. Keller Elizabeth J. Adams Rentian Wu Alexandre Côté Shilpi Arora Nico Cantone Rosana Meyer Jennifer A. Mertz Victor Gehling Jike Cui Jacob I. Stuckey Avinash Khanna Feng Zhao Zehua Chen Ziyang Yu Richard Cummings Mohammed Taimi Nehal J. Lakhani Drew Rasco Martin Gutierrez Linda Duska Michael Devitt Ronda Rippley Julian Levell Jennifer Truong Jing Wang Kaiming Sun Patrick Trojer

View Full Paper

Ask AI

Bookmark

Share

Abstract

Tulmimetostat treatment results in greater PRC2 target gene expression induction in phenotypically sensitive ARID1A LOF cell lines

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Keller et al. (2024) studied this question.

synapsesocial.com/papers/68e5e0e0b6db643587574da1 https://doi.org/10.1158/0008-5472.26423918.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S4 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers2024
2Supplementary Figure S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers2024
3Supplementary Figure S2 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers2024
4Supplementary Figure S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers2024
5Supplementary Figure S3 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers2024

More related papers

Supplementary Figure S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers2024
Supplementary Figure S7 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers2024
Supplementary Figure S6 from Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of <i>ARID1A</i> Mutant Cancers2024